Tag Archives: IMS

FDA: From Risk Aversion to Approval Activism

During the Rutgers Business School’s annual healthcare symposium, an FDA official encouraged industry to put its drugs on the reviewing table and be prepared for good news. On a panel titled “Activist FDA: Transformation Agent,” Prevision Policy founder and former Pink Sheet editorial head Cole Werble relayed the tale of Acadia Pharmaceuticals, a San Diego-based […]
Posted in Agency Insight, Biotech, FDA, leadership, Legal, Market Access, Orphan Drugs, People, R&D, Regulatory, Strategy | Also tagged , , , , , , | 2 Comments

Can Emerging Markets Emerge Fast Enough?

The IMS Institute’s annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy in Europe and the US?
Posted in Emerging Markets, Europe, Global, leadership, Market Access, pricing, Strategy | Also tagged , , , , | Leave a comment

Commercial Use of Physician Information Law Overturned

The ruling is likely to force state legislatures considering such bans to reconsider or fine tune their approach, as the First Amendment right to communicate appears to have trumped more parochial concerns about saving money on drugs. The US Court of Appeals for the Second Circuit recently ruled that a Vermont law restricting the commercial use […]
Posted in News | Also tagged | Leave a comment

Updated IMS Forecast Predicts Market Growth

If you look closely at the thunderclouds hovering over pharma, there is a ray of light peeking through the gloom—IMS’ updated 2009-2014 forecast has come in, and it’s a far cry from the unmitigated doom of recent years. Market growth in 2009 was 7 percent, a vast improvement over 2008’s 4.8 percent, and IMS expects […]
Posted in Strategy | Also tagged , , | Leave a comment
  • Categories

  • Meta